Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.47)
# 803
Out of 5,182 analysts
212
Total ratings
47.29%
Success rate
20.41%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $9.58 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $21.96 | +27.50% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $196.52 | -23.67% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $185.96 | -17.72% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $20.25 | -30.86% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $89.16 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $9.88 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $34.03 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $30.80 | +88.31% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $33.31 | +29.09% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $65.32 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.75 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $127.68 | +21.40% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.63 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $19.87 | +76.14% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $6.89 | +88.68% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.28 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.63 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $27.37 | +24.22% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $38.33 | +30.45% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $7.92 | -36.87% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.07 | +273.83% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $55.24 | +5.00% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.50 | +73,233.33% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.91 | +1,253.64% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.40 | +114.29% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $3.34 | +229.34% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $6.84 | +75.44% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.22 | +1,943.80% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.85 | +419.48% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $32.76 | +510.50% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $2.60 | +53.85% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.15 | +12,421.74% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.50 | +166.67% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $65.36 | -40.33% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $46.06 | -67.43% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.19 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $2.85 | +6,215.79% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.58
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $21.96
Upside: +27.50%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $196.52
Upside: -23.67%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $185.96
Upside: -17.72%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $20.25
Upside: -30.86%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $89.16
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.88
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $34.03
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $30.80
Upside: +88.31%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $33.31
Upside: +29.09%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $65.32
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.75
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $127.68
Upside: +21.40%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.63
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $19.87
Upside: +76.14%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $6.89
Upside: +88.68%
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.63
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $27.37
Upside: +24.22%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $38.33
Upside: +30.45%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $7.92
Upside: -36.87%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.07
Upside: +273.83%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $55.24
Upside: +5.00%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.50
Upside: +73,233.33%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.91
Upside: +1,253.64%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.40
Upside: +114.29%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $3.34
Upside: +229.34%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $6.84
Upside: +75.44%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.22
Upside: +1,943.80%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $3.85
Upside: +419.48%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $32.76
Upside: +510.50%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $2.60
Upside: +53.85%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.15
Upside: +12,421.74%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.50
Upside: +166.67%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $65.36
Upside: -40.33%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $46.06
Upside: -67.43%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.19
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $2.85
Upside: +6,215.79%